COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
SCARFO, L.; T. CHATZIKONSTANTINOU; G.M. RIGOLIN; G. QUARESMINI; M. MOTTA et al.
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Autoři
SCARFO, L.; T. CHATZIKONSTANTINOU; G.M. RIGOLIN; G. QUARESMINI; M. MOTTA; C. VITALE; J.A. GARCIA-MARCO; J.A. HERNANDEZ-RIVAS; F. MIRAS; M. BAILE; J. MARQUET; C.U. NIEMANN; G. REDA; T. MUNIR; E. GIMENO; M. MARCHETTI; F.M. QUAGLIA; M. VARETTONI; J. DELGADO; S. IYENGAR; A. JANSSENS; R. MARASCA; A. FERRARI; C. CUELLAR-GARCIA; G. ITCHAKI; M. SPACEK; L. DE PAOLI; L. LAURENTI; M.D. LEVIN; E. LISTA; F.R. MAURO; M. SIMKOVIC; E. VAN DER SPEK; E. VANDENBERGHE; L. TRENTIN; E. WASIK-SZCZEPANEK; R. RUCHLEMER; D. BRON; M.R. DE PAOLIS; G. DEL POETA; L. FARINA; M. FOGLIETTA; M. GENTILE; Y. HERISHANU; T. HEROLD; O. JAKSIC; A.P. KATER; S. KERSTING; L. MALERBA; L. ORSUCCI; V.M. POPOV; P. SPORTOLETTI; M. YASSIN; B. POCALI; G. BARNA; A. CHIARENZA; G. DOS SANTOS; E. NIKITIN; M. ANDRES; M. DIMOU; Michael DOUBEK; A. ENRICO; Y. HAKOBYAN; O. KALASHNIKOVA; M.O. PAREJA; M. PAPAIOANNOU; D. ROSSI; N. SHAH; A. SHRESTHA; O. STANCA; N. STAVROYIANNI; V. STRUGOV; C. TAM; M. ZDRENGHEA; M. COSCIA; K. STAMATOPOULOS; G. ROSSI; A. RAMBALDI; E. MONTSERRAT; R. FOA; A. CUNEO a P. GHIA
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (>= 65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (<= 12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
SCARFO, L.; T. CHATZIKONSTANTINOU; G.M. RIGOLIN; G. QUARESMINI; M. MOTTA; C. VITALE; J.A. GARCIA-MARCO; J.A. HERNANDEZ-RIVAS; F. MIRAS; M. BAILE; J. MARQUET; C.U. NIEMANN; G. REDA; T. MUNIR; E. GIMENO; M. MARCHETTI; F.M. QUAGLIA; M. VARETTONI; J. DELGADO; S. IYENGAR; A. JANSSENS; R. MARASCA; A. FERRARI; C. CUELLAR-GARCIA; G. ITCHAKI; M. SPACEK; L. DE PAOLI; L. LAURENTI; M.D. LEVIN; E. LISTA; F.R. MAURO; M. SIMKOVIC; E. VAN DER SPEK; E. VANDENBERGHE; L. TRENTIN; E. WASIK-SZCZEPANEK; R. RUCHLEMER; D. BRON; M.R. DE PAOLIS; G. DEL POETA; L. FARINA; M. FOGLIETTA; M. GENTILE; Y. HERISHANU; T. HEROLD; O. JAKSIC; A.P. KATER; S. KERSTING; L. MALERBA; L. ORSUCCI; V.M. POPOV; P. SPORTOLETTI; M. YASSIN; B. POCALI; G. BARNA; A. CHIARENZA; G. DOS SANTOS; E. NIKITIN; M. ANDRES; M. DIMOU; Michael DOUBEK; A. ENRICO; Y. HAKOBYAN; O. KALASHNIKOVA; M.O. PAREJA; M. PAPAIOANNOU; D. ROSSI; N. SHAH; A. SHRESTHA; O. STANCA; N. STAVROYIANNI; V. STRUGOV; C. TAM; M. ZDRENGHEA; M. COSCIA; K. STAMATOPOULOS; G. ROSSI; A. RAMBALDI; E. MONTSERRAT; R. FOA; A. CUNEO a P. GHIA. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. London: Nature Publishing Group, 2020, roč. 34, č. 9, s. 2354-2363. ISSN 0887-6924. Dostupné z: https://doi.org/10.1038/s41375-020-0959-x.
@article{1720337, author = {Scarfo, L. and Chatzikonstantinou, T. and Rigolin, G.M. and Quaresmini, G. and Motta, M. and Vitale, C. and GarciaandMarco, J.A. and HernandezandRivas, J.A. and Miras, F. and Baile, M. and Marquet, J. and Niemann, C.U. and Reda, G. and Munir, T. and Gimeno, E. and Marchetti, M. and Quaglia, F.M. and Varettoni, M. and Delgado, J. and Iyengar, S. and Janssens, A. and Marasca, R. and Ferrari, A. and CuellarandGarcia, C. and Itchaki, G. and Spacek, M. and De Paoli, L. and Laurenti, L. and Levin, M.D. and Lista, E. and Mauro, F.R. and Simkovic, M. and Van Der Spek, E. and Vandenberghe, E. and Trentin, L. and WasikandSzczepanek, E. and Ruchlemer, R. and Bron, D. and De Paolis, M.R. and Del Poeta, G. and Farina, L. and Foglietta, M. and Gentile, M. and Herishanu, Y. and Herold, T. and Jaksic, O. and Kater, A.P. and Kersting, S. and Malerba, L. and Orsucci, L. and Popov, V.M. and Sportoletti, P. and Yassin, M. and Pocali, B. and Barna, G. and Chiarenza, A. and dos Santos, G. and Nikitin, E. and Andres, M. and Dimou, M. and Doubek, Michael and Enrico, A. and Hakobyan, Y. and Kalashnikova, O. and Pareja, M.O. and Papaioannou, M. and Rossi, D. and Shah, N. and Shrestha, A. and Stanca, O. and Stavroyianni, N. and Strugov, V. and Tam, C. and Zdrenghea, M. and Coscia, M. and Stamatopoulos, K. and Rossi, G. and Rambaldi, A. and Montserrat, E. and Foa, R. and Cuneo, A. and Ghia, P.}, article_location = {London}, article_number = {9}, doi = {https://doi.org/10.1038/s41375-020-0959-x}, keywords = {CLINICAL CHARACTERISTICS; RISK-FACTORS; MULTICENTER; CANCER; CHINA}, language = {eng}, issn = {0887-6924}, journal = {Leukemia}, title = {COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus}, url = {https://www.nature.com/articles/s41375-020-0959-x.pdf}, volume = {34}, year = {2020} }
TY - JOUR ID - 1720337 AU - Scarfo, L. - Chatzikonstantinou, T. - Rigolin, G.M. - Quaresmini, G. - Motta, M. - Vitale, C. - Garcia-Marco, J.A. - Hernandez-Rivas, J.A. - Miras, F. - Baile, M. - Marquet, J. - Niemann, C.U. - Reda, G. - Munir, T. - Gimeno, E. - Marchetti, M. - Quaglia, F.M. - Varettoni, M. - Delgado, J. - Iyengar, S. - Janssens, A. - Marasca, R. - Ferrari, A. - Cuellar-Garcia, C. - Itchaki, G. - Spacek, M. - De Paoli, L. - Laurenti, L. - Levin, M.D. - Lista, E. - Mauro, F.R. - Simkovic, M. - Van Der Spek, E. - Vandenberghe, E. - Trentin, L. - Wasik-Szczepanek, E. - Ruchlemer, R. - Bron, D. - De Paolis, M.R. - Del Poeta, G. - Farina, L. - Foglietta, M. - Gentile, M. - Herishanu, Y. - Herold, T. - Jaksic, O. - Kater, A.P. - Kersting, S. - Malerba, L. - Orsucci, L. - Popov, V.M. - Sportoletti, P. - Yassin, M. - Pocali, B. - Barna, G. - Chiarenza, A. - dos Santos, G. - Nikitin, E. - Andres, M. - Dimou, M. - Doubek, Michael - Enrico, A. - Hakobyan, Y. - Kalashnikova, O. - Pareja, M.O. - Papaioannou, M. - Rossi, D. - Shah, N. - Shrestha, A. - Stanca, O. - Stavroyianni, N. - Strugov, V. - Tam, C. - Zdrenghea, M. - Coscia, M. - Stamatopoulos, K. - Rossi, G. - Rambaldi, A. - Montserrat, E. - Foa, R. - Cuneo, A. - Ghia, P. PY - 2020 TI - COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus JF - Leukemia VL - 34 IS - 9 SP - 2354-2363 EP - 2354-2363 PB - Nature Publishing Group SN - 08876924 KW - CLINICAL CHARACTERISTICS KW - RISK-FACTORS KW - MULTICENTER KW - CANCER KW - CHINA UR - https://www.nature.com/articles/s41375-020-0959-x.pdf L2 - https://www.nature.com/articles/s41375-020-0959-x.pdf N2 - Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (>= 65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (<= 12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency. ER -
SCARFO, L.; T. CHATZIKONSTANTINOU; G.M. RIGOLIN; G. QUARESMINI; M. MOTTA; C. VITALE; J.A. GARCIA-MARCO; J.A. HERNANDEZ-RIVAS; F. MIRAS; M. BAILE; J. MARQUET; C.U. NIEMANN; G. REDA; T. MUNIR; E. GIMENO; M. MARCHETTI; F.M. QUAGLIA; M. VARETTONI; J. DELGADO; S. IYENGAR; A. JANSSENS; R. MARASCA; A. FERRARI; C. CUELLAR-GARCIA; G. ITCHAKI; M. SPACEK; L. DE PAOLI; L. LAURENTI; M.D. LEVIN; E. LISTA; F.R. MAURO; M. SIMKOVIC; E. VAN DER SPEK; E. VANDENBERGHE; L. TRENTIN; E. WASIK-SZCZEPANEK; R. RUCHLEMER; D. BRON; M.R. DE PAOLIS; G. DEL POETA; L. FARINA; M. FOGLIETTA; M. GENTILE; Y. HERISHANU; T. HEROLD; O. JAKSIC; A.P. KATER; S. KERSTING; L. MALERBA; L. ORSUCCI; V.M. POPOV; P. SPORTOLETTI; M. YASSIN; B. POCALI; G. BARNA; A. CHIARENZA; G. DOS SANTOS; E. NIKITIN; M. ANDRES; M. DIMOU; Michael DOUBEK; A. ENRICO; Y. HAKOBYAN; O. KALASHNIKOVA; M.O. PAREJA; M. PAPAIOANNOU; D. ROSSI; N. SHAH; A. SHRESTHA; O. STANCA; N. STAVROYIANNI; V. STRUGOV; C. TAM; M. ZDRENGHEA; M. COSCIA; K. STAMATOPOULOS; G. ROSSI; A. RAMBALDI; E. MONTSERRAT; R. FOA; A. CUNEO a P. GHIA. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. \textit{Leukemia}. London: Nature Publishing Group, 2020, roč.~34, č.~9, s.~2354-2363. ISSN~0887-6924. Dostupné z: https://doi.org/10.1038/s41375-020-0959-x.